FROST & SULLIVAN

Frost Radar™: Intelligent Imaging Analysis Systems, 2026

A Benchmarking System to Spark Companies to Action - Innovation That Fuels New Deal Flow and Growth Pipelines

DB56-TV
2026

FROST & SULLIVAN

Strategic Imperative and Growth Environment



Strategic Imperative

- Medical imaging techniques, including but not limited to computed tomography (CT), X-ray radiography, and magnetic resonance imaging (MRI), are invaluable tools for radiologists and clinicians in disease diagnosis and treatment efficacy assessment.
- The current practice of manually viewing and grading medical images to identify any abnormalities is time-consuming and can delay diagnosis for critical patients. The method is also prone to error: the interpretation of a medical image is subjective and influenced by the professional's level of expertise. Because of the complexity of the images, intra- and inter-reader variability can arise.
- Intelligent imaging analysis systems that use artificial intelligence (AI), deep learning (DL), and machine learning (ML) algorithms are gaining traction. They can scan through huge volumes of medical images to detect abnormalities quickly. Because the systems are trained on numerous medical images, they can precisely quantify and segregate abnormal structures from normal ones and present results to healthcare professionals for final review and more accurate diagnoses.
- Intelligent imaging analysis systems are device agnostic and can be hosted on the cloud. This has facilitated virtual radiology, providing access to high-quality diagnostic images that can be reviewed by radiologists anywhere in the world so that underserved patient populations have access to care.
- The systems can identify diseases in early stages and provide more accurate patient risk stratification, setting a new standard in the quality of care.

Source: Frost & Sullivan

Growth Environment

- The market for intelligent imaging analysis systems for automated identification, decision support, and diagnosis is poised for strong growth, allowing healthcare providers across the globe to keep pace with the volume of diagnostic imaging procedures despite a shortage of radiologists and trained clinicians. Radiologists and clinicians see these systems as a tool to augment their capabilities and perform more value-added tasks.
- Although initial adoption was primarily in North America and Europe, their utility has led to gradual proliferation in Asia-Pacific, Latin America, the Middle East, and Africa.
- The market has been predominantly driven by specialist AI software developers and start-ups, but traditional medical imaging vendors have also been increasing their presence in this area. Interest from government bodies and private investors is likely to spur the entry of new players.
- Market trends include collaborations between medical imaging companies, healthcare institutions, and imaging service providers, along with the use of fee-per-study business models.

Source: Frost & Sullivan

FROST & SULLIVAN

Frost Radar™

Intelligent Imaging Analysis Systems



Source: Frost & Sullivan

Frost Radar™: Intelligent Imaging Analysis Systems



FROST & SULLIVAN

Source: Frost & Sullivan

Frost Radar™ Competitive Environment

- From a field of more than 50 industry participants, Frost & Sullivan independently plotted the top 10 companies in this Frost Radar ™ analysis: Siemens Healthineers AG, Nanox Ltd, RapidAI Inc, Ultromics Limited, Brainomix Ltd, Viz.ai Inc., Qure.ai Technologies Private Limited, Aidoc Medical Ltd., Riverain Technologies Inc, and icometrix NV. These companies to action have identified the needs of health professionals and patients and met them with their outstanding innovations.
- Companies offering intelligent imaging analysis software applications in the areas of brain, lung, liver, bone, prostate, and cardiac imaging were included in the analysis. Only US Food and Drug Administration (FDA)/CE or other regulatory-approved software is profiled in this Frost Radar. ™
- RapidAI is among the leaders in this space because of its sustained focus on developing bundled AI imaging solutions for diagnosis and patient management of various conditions aimed at improving patient outcomes.

Source: Frost & Sullivan

FROST & SULLIVAN

Frost Radar™

Companies to Action



Source: Frost & Sullivan

RapidAI, United States

INNOVATION

- RapidAI provides solutions that use AI and ML algorithms for triaging non-contrast CT, CTA, CT perfusion, and MRI for notifying of possible cases related to neurovascular, cardiovascular, oncology and trauma conditions. A sample of RapidAI neurovascular solutions include Rapid ICH + Hyperdensity used for detecting all suspected acute hemorrhage types, and ischemic solutions for detecting large and medium vessel occlusions and quantifying the impacted vasculature. RapidAI cardiovascular solutions consist of Rapid Aortic for identifying and monitoring patients with aortic aneurysms and Rapid PE Triage & Notification for triaging pulmonary embolism cases. The platform offers various third-party algorithms for spine, lung, iPE, etc.
- All data from the RapidAI platforms feeds into RapidAI Insights, which offers dashboards to clinicians for better program decision-making.
- RapidAI solutions are extensively validated across more than 1,000 clinical studies that have been published in at least 700 peer-reviewed publications.
- The technology used in the RapidAI platform is unique and scalable. The solutions are CE marked and have 30 US FDA-cleared modules.
- The company has raised more than $100 million from investors, such as Vista Credit Partners and Lennertz & Co.
- RapidAI scored 4.8 on the Frost Radar™ Innovation Index.

Source: Frost & Sullivan

RapidAI, United States (continued)

GROWTH

- The RapidAI platform has been deployed in over 2,500 hospitals across more than 100 countries including the United States, Argentina, Saudi Arabia, Taiwan, Japan, and Brazil, demonstrating its commitment to treat acute and chronic conditions across the globe.
- The Rapid Enterprise Platform provides a one-stop shop for healthcare providers looking for solutions for standardizing care for time-sensitive conditions, such as stroke or chronic conditions such as cerebral aneurysms and aortic management, improving patient health outcomes while at the same time optimizing operational efficiencies.
- In December 2025, RapidAI partnered with Amazon Web Services to leverage the latter's AI infrastructure and ML pipelines to deliver more adaptive and clinically validated AI designed to improve diagnostic precision, streamline workflows, and expand access to life-saving technologies worldwide.
- RapidAI scored 3.4 on the Frost Radar Growth Index™.

Source: Frost & Sullivan

RapidAI, United States (continued)

FROST PERSPECTIVE

- With over 20 million scans performed by the RapidAI platform till December 2025, the company can harness this data to improve the functionality and performance of its solutions.
- The acquisition of EndoVantage has cemented RapidAI's position in the cerebral aneurysm management space.
- The recent capital infusion can also be used to determine the feasibility of RapidAI platforms for other cerebrovascular diseases, such as carotid stenosis and vascular malformations.

Source: Frost & Sullivan

FROST & SULLIVAN

Best Practices & Growth Opportunities

Source: Frost & Sullivan

Best Practices

1. It is imperative for companies to offer patient-centric, efficacious, and easy-to-use AI-powered imaging analysis software products to maintain their competitive edge in the market. It is important for companies to target broad disease conditions; focusing on limited cardiac, respiratory, and brain conditions restricts wider adoption.

2. Awareness of AI-powered imaging analysis software solutions is essential for wider market acceptance. Large companies with deep pockets have so far been at the forefront of raising awareness about the technology. It is imperative for other companies to contribute to this effort.

3. Companies must integrate adaptive intelligence into AI-powered imaging analysis software to improve their decision-making ability based on feedback and results. This self-learning ability can reduce the time required to detect anomalies in medical images and improve patient outcomes.

Source: Frost & Sullivan

Growth Opportunities

1. Despite radiologists' initial apprehensions about AI replacing them, intelligent imaging analysis systems are becoming invaluable tools in medical imaging because of their ability to increase diagnostic accuracy and improve productivity. The systems played a crucial role during the COVID-19 pandemic through faster diagnosis of cases, significantly reducing clinician workload and improving patient outcomes.

2. Companies operating in this space need to build partnerships with healthcare providers and government agencies to get access to curated imaging datasets that are technically and demographically diverse and free of bias for developing their algorithms. A dynamic research loop in which client feedback is incorporated to refine platform functionality can go a long way in developing solutions that are closely aligned to customer needs.

3. AI-powered imaging analysis software developers can move from just image analysis for detecting abnormalities to guided image acquisition and stratification of patients based on the best treatment options.

Source: Frost & Sullivan

FROST & SULLIVAN

Frost Radar™ Analytics



Source: Frost & Sullivan

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

HORIZONTAL AXIS

Innovation Index (II) is a measure of a company's ability to develop products/services/solutions with a clear understanding of industry needs and requirements that are globally applicable, are able to evolve and expand to serve multiple markets, and are aligned to customers' changing needs by leveraging its technology.

INNOVATION INDEX ELEMENTS

- **II1: SCALABILITY**
  This determines the ability of the company to scale its technology to meet product demand over the next 2 years
- **II2: IP COMPETITIVENESS**
  This is a measure of the strength of the company's IP portfolio for its technology
- **II3: DISRUPTION POTENTIAL**
  This is a measure of a company's ability to differentiate its technology against competing technologies
- **II4: DEPLOYMENT READINESS**
  This is an assessment of the readiness of the company's technology for commercial deployment
- **II5: R&D INVESTMENT**
- This evaluates the applicability of a company's products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Source: Frost & Sullivan

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

VERTICAL AXIS

Growth Index (GI) is a measure of a company's growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision using the developed technology.

GROWTH INDEX ELEMENTS

- **GI1: APPLICATION DIVERSITY**
  This is a measure of the company's ability to deploy its technology for use in targeted applications across industries
- **GI2: REVENUE POTENTIAL**
  This is a look at a company's cumulative revenue potential for the next five years that can be obtained from the technology that forms the context for the given Frost Radar™
- **GI3: ADOPTION POTENTIAL**
  This is an evaluation of the ability of the company to ensure the availability of its developed technology across geographies in the period of next six months to one year when the Frost Radar ™is being evaluated.
- **GI4: PARTNERSHIP ECOSYSTEM**
  This is an assessment of how well a company is building successful partnerships for value creation and monetization across the technology ecosystem
- **GI5: PRODUCT PIPELINE**
- This is a measure of the effectiveness of a company to develop a number of products/product grades enabled by technology with commercialization potential in a period of six months to one year when the Frost Radar™ is being evaluated.

Source: Frost & Sullivan

Next Steps

JOIN:
Growth Council

APPLY:
Companies to Action

ENGAGE:
Growth Dialog

PARTICIPATE:
Growth Council Think Tank

Does your current system support rapid adaptation to emerging opportunities?

Source: Frost & Sullivan

Legal Disclaimer

Frost & Sullivan is not responsible for any incorrect information supplied by companies or users. Quantitative market information is based primarily on interviews and therefore is subject to fluctuation. Frost & Sullivan research services are limited publications containing valuable market information provided to a select group of customers. Customers acknowledge, when ordering or downloading, that Frost & Sullivan research services are for internal use and not for general publication or disclosure to third parties. No part of this research service may be given, lent, resold, or disclosed to noncustomers without written permission. Furthermore, no part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means—electronic, mechanical, photocopying, recording, or otherwise—without the permission of the publisher.

For information regarding permission, write to: permission@frost.com

Source: Frost & Sullivan